$sup 111$In-bleomycin breast and axilla imaging

Conference · Thu Jan 01 04:00:00 EST 1976 · Cancer, v. 37, no. 1, pp. 36-42

OSTI ID:4038224

Silverstein, M J; Verma, R C; Greenfield, L; Morton, D L

$sup 111$Indium-Bleomycin ($sup 111$In-Blm), a new radiopharmaceutical, was administered intravenously to 37 patients with benign and malignant breast lesions. Early and delayed images of both the breasts and axillae were made, and results were correlated with physical examination, histopathology of the excised lesion, mammography, and thermography. In 18 patients with malignant disease, clinical examination of the breast and axilla correlated with histopathology in 78 and 54 percent of the cases, respectively. Images of the breast were accurate (true positives) in 83 percent of the cases. Images of the axilla were accurate in 62 percent of the cases. Mammography was correct and suggested malignancy in 88 percent, and thermography in 73 percent of the cases. In 19 patients with benign breast lesions, clinical examination of the breast and axilla correlated with histopathology in 68 and 95 percent of the cases, respectively. Scans of the breast and axilla were correct (true negative) 79 and 95 percent of the time, respectively. Mammography was correct, and suggested benignancy, in 53 percent and thermography in 25 percent of the cases. Imaging of the breasts using $sup 111$In-Blm appears to be as accurate as physical examination and mammography for palpable benign and malignant breast tumors. (auth)

• Research Organization: Univ. of California, Los Angeles
• NSA Number: NSA-33-029946
• OSTI ID: 4038224
• Conference Information: Journal Name: Cancer, v. 37, no. 1, pp. 36-42
• Country of Publication: United States
• Language: English

Related Subjects

*BLEOMYCIN
*MAMMARY GLANDS-- SCINTISCANNING
550601* --Biomedical Sciences
Basic Studies--Medicine-- Unsealed Radionuclides in Diagnostics
BIOMEDICAL RADIOGRAPHY
IMAGES
N48830* --Life Sciences--New Tracer Techniques--Other
PATHOLOGY
PATIENTS
TRACER TECHNIQUES